Method for T Lymphocyte Immunosupression
Tech ID: 96-04
Summary - Researchers from National Jewish Health have developed and tested a novel method for T lymphocyte immunosuppression. The technology is based on conjugating a CD4 or CD2 molecule with an antibody specific for a cell surface marker. Therefore this technology inhibits CD4+ or CD4+ together with CD8+ T cells, respectively, immune stimulatory cells, without affecting other immune functions.
Potential Applications
- Graft rejection
- Autoimmune diseases
Advantages of Invention - Only lymphocytes that are specific for antigens found on the grafted cells are target, eliminating any broad immunosuppression currently obtained with traditional treatments.
State of Development - Technology has been demonstrated in vitro to inhibit CD4+ T cells by conjugating engineered antibody that express CD4 or CD2 molecules onto immune stimulatory cells.
Further R&D Required - Demonstrating the efficacy of the technology in vivo.
Patent - US patents # 6,060,054 and 6,264,950
Publication
Inventors - Uwe Staerz, MD, PhD
Licensing Status - This technology is available for licensing
For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
HilaireE@njhealth.org
